Trial Outcomes & Findings for Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers (NCT NCT04251819)

NCT ID: NCT04251819

Last Updated: 2026-01-07

Results Overview

Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Recruitment status

TERMINATED

Study phase

PHASE2/PHASE3

Target enrollment

19 participants

Primary outcome timeframe

Baseline

Results posted on

2026-01-07

Participant Flow

Participant milestones

Participant milestones
Measure
Placebo
Participants randomized to this arm will receive Placebo.
Baclofen 5mg
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 10mg
Participants randomized to this arm will receive 10 mg of Baclofen.
Overall Study
STARTED
6
8
5
Overall Study
COMPLETED
6
8
5
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Total
n=38 Participants
Total of all reporting groups
Age, Continuous
27.17 years
STANDARD_DEVIATION 12.58 • n=6 Participants
36.63 years
STANDARD_DEVIATION 11.89 • n=8 Participants
22.8 years
STANDARD_DEVIATION 2.59 • n=5 Participants
29.58 years
STANDARD_DEVIATION 11.46 • n=19 Participants
Sex: Female, Male
Female
2 Participants
n=6 Participants
8 Participants
n=8 Participants
2 Participants
n=5 Participants
12 Participants
n=19 Participants
Sex: Female, Male
Male
4 Participants
n=6 Participants
0 Participants
n=8 Participants
3 Participants
n=5 Participants
7 Participants
n=19 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
1 Participants
n=19 Participants
Race (NIH/OMB)
Asian
0 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=6 Participants
2 Participants
n=8 Participants
0 Participants
n=5 Participants
2 Participants
n=19 Participants
Race (NIH/OMB)
White
5 Participants
n=6 Participants
4 Participants
n=8 Participants
2 Participants
n=5 Participants
11 Participants
n=19 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=6 Participants
2 Participants
n=8 Participants
3 Participants
n=5 Participants
5 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
0 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
n=6 Participants
8 Participants
n=8 Participants
5 Participants
n=5 Participants
19 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=6 Participants
0 Participants
n=8 Participants
0 Participants
n=5 Participants
0 Participants
n=19 Participants
Region of Enrollment
United States
6 Participants
n=6 Participants
8 Participants
n=8 Participants
5 Participants
n=5 Participants
19 Participants
n=19 Participants

PRIMARY outcome

Timeframe: Baseline

Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Pain Threshold
43.56 Degrees Celsius
Standard Deviation 3.77
45.11 Degrees Celsius
Standard Deviation 3.04
44.62 Degrees Celsius
Standard Deviation 2.13

PRIMARY outcome

Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Pain Threshold
42.06 Degrees Celsius
Standard Deviation 3.14
43.95 Degrees Celsius
Standard Deviation 2.70
43.82 Degrees Celsius
Standard Deviation 2.46

PRIMARY outcome

Timeframe: Baseline

Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Pain Tolerance
47.34 Degrees Celsius
Standard Deviation 2.11
46.84 Degrees Celsius
Standard Deviation 2.00
48.17 Degrees Celsius
Standard Deviation 1.52

PRIMARY outcome

Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Pain Tolerance
46.36 Degrees Celsius
Standard Deviation 2.56
47.70 Degrees Celsius
Standard Deviation 2.20
47.84 Degrees Celsius
Standard Deviation 1.86

PRIMARY outcome

Timeframe: Baseline

Population: Data were missing.

Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=4 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=5 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Temporal Summation of Pain
60.25 units on a scale
Standard Deviation 35.3
48.4 units on a scale
Standard Deviation 35.5
43.2 units on a scale
Standard Deviation 8.0

PRIMARY outcome

Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=3 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Temporal Summation of Pain
36.7 units on a scale
Standard Deviation 23.6
64.5 units on a scale
Standard Deviation 23.0
47.6 units on a scale
Standard Deviation 17.5

PRIMARY outcome

Timeframe: Baseline

Population: Data were missing.

A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus). Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn. Pain rating scores for the test stimulus and the conditioning stimulus will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain. The conditioned pain modulation score is the difference between the two pain rating scores.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=7 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Conditioned Pain Modulation
-2.0 units on a scale
Standard Deviation 5.7
2.1 units on a scale
Standard Deviation 15.5
-0.2 units on a scale
Standard Deviation 7.4

PRIMARY outcome

Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus). Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn. Pain rating scores for the test stimulus and the conditioning stimulus will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain. The conditioned pain modulation score is the difference between the two pain rating scores.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=4 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Conditioned Pain Modulation
-6.3 units on a scale
Standard Deviation 4.8
-10.8 units on a scale
Standard Deviation 15.0
3.0 units on a scale
Standard Deviation 5.7

PRIMARY outcome

Timeframe: Baseline

Population: Data were missing.

Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Suprathreshold Pain Response
53.4 units on a scale
Standard Deviation 37.6
54.2 units on a scale
Standard Deviation 34.7
42.5 units on a scale
Standard Deviation 20.4

PRIMARY outcome

Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Suprathreshold Pain Response
54.0 units on a scale
Standard Deviation 30.7
68.8 units on a scale
Standard Deviation 20.8
36.0 units on a scale
Standard Deviation 15.2

SECONDARY outcome

Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Measures the amount and intensity of side effects after being administered an opioid. The measure consists of 14 questions about potential opioid symptoms, and each the severity of the symptom is rated on a scale from 0 to 4, with 0 reflecting not at all feeling or being bothered by the symptom and 4 reflecting being severely bothered by the symptom. The score is the sum of the 14 responses. The minimum value is 0 and the maximum value is 56.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Opioid Symptom Checklist
0.60 units on a scale
Standard Deviation 0.54
0.75 units on a scale
Standard Deviation 1.39
4.67 units on a scale
Standard Deviation 4.08

SECONDARY outcome

Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Measures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication. The measure consists of 7 questions about potential drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all feeling the effect and 100 reflecting very much feeling the effect. The score is the sum of the 7 responses. The minimum value is 0 and the maximum value is 700.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
26-item Visual Analog Scale (VAS)
120.2 units on a scale
Standard Deviation 76.9
50.4 units on a scale
Standard Deviation 88.5
180.7 units on a scale
Standard Deviation 94.3

SECONDARY outcome

Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

Population: Data were missing.

Measures subjective experiences of a drug. The measure consists of 5 questions about the participant's experience of the drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all having an experience and 100 reflecting extremely having that experience. The score is the sum of the 5 responses. The minimum value is 0 and the maximum value is 500.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=7 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Drug Effects Questionnaire-5
103.8 units on a scale
Standard Deviation 65.9
101.1 units on a scale
Standard Deviation 76.0
168.8 units on a scale
Standard Deviation 106.7

SECONDARY outcome

Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visit

This 26-item VAS measures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication. The measure consists of 7 questions about potential drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all feeling the effect and 100 reflecting very much feeling the effect. The score is the sum of the 7 responses. The minimum value is 0 and the maximum value is 700.

Outcome measures

Outcome measures
Measure
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
26-item Visual Analog Scale ("Subjective Drug Effects")
120.2 units on a scale
Standard Deviation 76.9
50.4 units on a scale
Standard Deviation 88.5
180.7 units on a scale
Standard Deviation 94.3

Adverse Events

Placebo

Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths

Baclofen 5mg

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Baclofen 10mg

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Placebo
n=6 participants at risk
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 participants at risk
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 10mg
n=5 participants at risk
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Injury, poisoning and procedural complications
Emergency Department Visit
16.7%
1/6 • Number of events 1 • From baseline to 48 hours after dose session
0.00%
0/8 • From baseline to 48 hours after dose session
0.00%
0/5 • From baseline to 48 hours after dose session

Other adverse events

Other adverse events
Measure
Placebo
n=6 participants at risk
Participants randomized to this arm will receive Placebo. Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 5mg
n=8 participants at risk
Participants randomized to this arm will receive 5 mg of Baclofen. Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Baclofen 10mg
n=5 participants at risk
Participants randomized to this arm will receive 10 mg of Baclofen. Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Injury, poisoning and procedural complications
Buprenorphine Poisoning
16.7%
1/6 • Number of events 1 • From baseline to 48 hours after dose session
0.00%
0/8 • From baseline to 48 hours after dose session
0.00%
0/5 • From baseline to 48 hours after dose session

Additional Information

Karen Cropsey

UAB

Phone: 2059754204

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place